New study tracks Elacestrant's Real-World impact on advanced breast cancer

NCT ID NCT07563595

Recruiting now Knowledge-focused Sponsor: iOMEDICO AG Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 500 postmenopausal women with advanced ER+ HER2- breast cancer that has an ESR1 mutation. Participants receive elacestrant as part of their normal care. Researchers will track quality of life, side effects, and how the cancer responds over time. The goal is to understand how well this drug works outside of clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Elacestrant (Orserdu®)
What this could lead to: If successful, this study could provide real-world evidence on how well elacestrant controls advanced breast cancer and improves quality of life for patients with ESR1 mutations.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It does not test a new treatment but gathers data on existing use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Gemeinschaftspraxis für Hämatologie und Onkologie
RECRUITING

Ravensburg, 88212, Germany
Praxis für interdisziplinäre Onkologie & Hämatologie
RECRUITING

Freiburg im Breisgau, 79110, Germany
St. Louise Frauen- und Kinderklinik
RECRUITING

Paderborn, 33098, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.